

Pakistan Veterinary Journal

ISSN: 0253-8318 (PRINT), 2074-7764 (ONLINE) DOI: 10.29261/pakvetj/2021.062

RESEARCH ARTICLE

Genetic Characterization of Equine Herpesvirus 1 from Clinical Cases and Asymptomatic Horses in Serbia and Bosnia and Herzegovina

Andrea Radalj¹*, Nenad Milić¹, Oliver Stevanović², Ljubiša Veljović³ and Jakov Nišavić¹

¹Department of Microbiology, University of Belgrade, Faculty of Veterinary Medicine, Blvd. Oslobodjenja 18, 11000 Belgrade, Serbia; ² Veterinary Institute of the Republic of Srpska "Dr. Vaso Butozan", Branka Radičevića 18, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina; ³Virology Department, Institute of Veterinary Medicine of Serbia, Janulisa 14, 11000 Belgrade, Serbia

*Corresponding author: andrea.zoric@vet.bg.ac.rs

ARTICLE HISTORY (21-148)

Received: April 03, 2021 Revised: June 28, 2021 Accepted: July 14, 2021 Published online: August 25, 2021 Key words: EHV-1 Horse Infection ORF30 ORF68 Sequencing

ABSTRACT

Equine herpesvirus 1 (EHV-1) causes considerable economic loss to the equine industry and is spread among susceptible animals during the cycles of latency and reactivation, causing rhinopneumonitis, abortion, and neurological disease. Nucleotide polymorphisms within ORF30 and ORF68 sequences of the viral genome are associated with strain neuropathogenicity and geographical origin. A total of 142 tissue and nasal swab samples from apparently healthy unvaccinated horses were examined to ascertain EHV-1 distribution, diversity, and clinical significance considering the results of virus isolation, sequence analysis, and anamnestic data. The ORF30 and ORF68 molecular study of these circulating strains and archival isolates from abortion storms aimed to contribute to the perception of strain pathogenicity and origin. EHV-1 was detected by PCR and virus isolation in 81 and 45.1% of the analyzed samples, respectively, and 82.1% of the representative samples were neuropathogenic strains. The ORF68-based grouping was restricted by the pronounced polymorphism of Balkan EHV-1 strains, and only two isolates were assigned to group 4. The cases of abortion were caused by neuropathogenic strains that also circulate within the horse population with no documented outbreaks of disease. It was evident that strain virulence is not solely accountable for the development of clinical symptoms in affected animals. Neural tissue is significant for virus latency and reactivation, considering the number of EHV-1 isolates from apparently healthy stressed horses. Special care must be taken when accommodating together immunologically naive and latently infected horses since asymptomatic carriers silently shed EHV-1.

To Cite This Article: Radalj A, Milić N, Stevanović O, Veljović L and Nišavić J, 2021. Genetic characterization of equine herpesvirus 1 from clinical cases and asymptomatic horses in Serbia and Bosnia and Herzegovina. Pak Vet J, 41(4): 567-573. http://dx.doi.org/10.29261/pakvetj/2021.062

INTRODUCTION

Equine herpesvirus 1 (EHV-1) belongs to the genus *Varicellovirus* of the *Alphaherpesvirinae* subfamily and represents an important equine pathogen with a worldwide distribution (Slater, 2014). The 150 kb long linear double-stranded DNA genome of this virus contains 80 open reading frames (ORFs), and some are variable making them convenient for genetic analysis (Nugent *et al.*, 2006; Slater, 2014). Most EHV-1 infections are subclinical, however, it is known to cause respiratory disease (rhinopneumonitis), abortion in pregnant mares, and neurological disease of variable severity (Barbić *et al.*, 2012; Slater, 2014; Castro and Arbiza, 2017; Preziuso *et*

al., 2019; Pusterla *et al.*, 2021). The virus is excreted through nasal secretions and it is present in high titers in the placenta and aborted fetuses, hence its transmission in the susceptible population mostly occurs through direct contact (Wang *et al.*, 2007; Damiani *et al.*, 2014; Slater, 2014; Pusterla *et al.*, 2021). After primo-infection, EHV-1 establishes latency in the trigeminal ganglia and leucocytes and is reactivated by factors that contribute to immunosuppression, such as stress (Slater *et al.*, 1994; Allen *et al.*, 2008; Pusterla *et al.*, 2012; Giessler *et al.*, 2020; Samoilowa *et al.*, 2021). Abortion in pregnant mares commonly occurs during the third trimester, and a high neonatal foal mortality rate is due to interstitial pneumonia complications (Turan *et al.*, 2012; Slater,

2014; Stasiak et al., 2020). Neurological disease caused by EHV-1 is termed equine herpesvirus myeloencephalopathy (EHM) and is characterized by mild ataxia to complete paralysis depending on the diameter and localization of the affected area of the central nervous system (Lunn et al., 2009; Gryspeerdt et al., 2011; Barbić et al., 2012; Negusie et al., 2017; Pusterla et al., 2021). Highly virulent strains, such as Ab4, are endotheliotropic, establish high levels of cell-associated viremia, cause abortion and neurological disease, while others, like V592, are less virulent and are not connected to severe clinical outcomes (Nugent et al., 2006; Goodman et al., 2007). Genome sequencing is applied for the analysis of EHV-1 genetic mutations and global tracking of the spread of various strains (Nugent et al., 2006; Milić et al., 2017; Kang et al., 2021; Pusterla et al., 2021). A difference between the sequences of Ab4 and V592 represented by a single nucleotide polymorphism (SNP) was detected within the ORF30 region that is widely used as a molecular marker for neuropathogenicity (Nugent et al., 2006; Garvey et al., 2019; Kang et al., 2021). The nucleotide substitution of adenine (A) with guanine (G) on position 2254 (A_{2254} to G_{2254}) leads to the substitution of amino acids (asparagine - N to aspartic acid - D) at position 752 as the probable cause of altered function of EHV-1 DNA polymerase and heightened levels of cellassociated viremia due to more efficient viral replication within leucocytes (Nugent et al., 2006; Goodman et al., 2007; Giessler et al., 2020; Samoilowa et al., 2021). Particular genetic polymorphism of up to 2% amongst EHV-1 strains was discovered within the ORF68 region that has been used as an epidemiological marker for the creation of several geographic groups (Nugent et al., 2006; Malik et al., 2012; Stasiak et al., 2017; Matczuk et al., 2018; Stasiak et al., 2020; Kang et al., 2021).

The first isolation of EHV-1 in former Yugoslavia (on the territory of Serbia) was carried out at the Faculty of Veterinary Medicine, the University of Belgrade from the samples of aborted fetuses (liver, spleen, lungs, placenta, and amniotic fluid) after abortion storms that occurred at the "Ljubičevo" stud farm during the 1980s. These EHV-1 isolates are kept at the Laboratory for Virology at the Department for Microbiology. Since genotyping studies concerning the ORF30 and ORF68 genes have never been performed in this region, this study aimed to analyze these archival EHV-1 isolates and samples originating from clinically healthy unvaccinated animals to determine the diversity and clinical implications of the circulating EHV-1 strains.

MATERIALS AND METHODS

Samples: Samples originated from clinically healthy unvaccinated horses and included 100 tissue samples (submandibular lymph nodes, spleen, medulla, and spinal cord) collected from 25 abattoir horses (four samples per horse) and 42 nasal swabs. Tissue samples were collected in Serbia from Lipizzaner or mixed breed horses reared on individual farms in various districts: South Bačka, Srem, Central Banat, Belgrade, Mačva, Braničevo, and Bor. Samples of nasal swabs originated from horses in the Republic of Srpska (Bosnia and Herzegovina) at a stud farm in the Municipality of Prnjavor. Swabs were taken

from clinically healthy Lipizzaner horses except for one yearling with marked respiratory symptoms. The horses were located in three individual stables in different locations within the stud: two stables with 16 mares each and one stable with 10 stallions. The mares within each object were all in direct contact since the indoors were not separated by fences or boxes. Sample availability from unvaccinated animals was limited due to regular vaccination strategies on major studs and the diminishing number of horses held in the private sector combined with the owner's unwillingness to allow animal manipulation. Additionally, four lyophilized EHV-1 strains isolated in the 1980s during abortion storms in the "Ljubičevo" stud farm at the Braničevo District were subjected to testing.

The samples were homogenized in PBS, and after centrifuging (10 min at 1,677 \times g), the obtained supernatants were filtered prior to cell culture inoculation. The GeneJET Genomic DNA Purification Kit (Thermo Scientific, USA) was used for DNA extraction from the remaining cell debris.

Virus isolation: Virus isolation was carried out using rabbit kidney-13 cell line (RK-13) with uninoculated monolayers used as controls (Fig. 1). The EHV-1 positive control strain was delivered by The Scientific Veterinary Institute of Serbia.

PCR: Nested PCR was performed to confirm the presence of EHV-1 in inoculated cells with visible CPE, and to directly examine all tissue and nasal swab samples (Wang et al., 2007). Positive samples were analyzed using PCR for gene regions ORF30 and ORF68 (Nugent et al., 2006). A 466bp region of ORF30 was amplified as described by Goodman et al. (2007). Primers for the 645bp region of ORF68 described by Nugent et al. (2006) and PCR conditions by Negussie et al. (2017) were applied. After preliminary unsuccessful tests, a modified protocol was carried out: 95°C (3 min), 30 cycles at 94°C (30 s), 50°C (1 min), 72°C (1 min), and 72°C for 6 min. Equine herpesvirus 5 DNA (laboratory internal reference strain) represented a negative control, while the positive control used for virus isolation also served as a positive PCR control. In order to prepare the PCR products of the amplified ORF68 gene segment for sequencing, the obtained bands were excised from the agarose gel and purified using PureLink Quick Gel Extraction Kit (Invitrogen, United Kingdom).

ORF30 and ORF68 sequence analysis and phylogeny: The samples were sent for sequencing to the Macrogen Europe Laboratory in Amsterdam (Netherlands). The sequences were aligned and analyzed with virus sequences from the GenBank database using BLAST tool (http://www.ncbi.nlm.nih.gov/BLAST). Selected ORF30 and ORF68 sequences were aligned and compared with reference virus sequences available in GenBank for the presence of SNPs using BioEdit 7.2.5. software. Evolutionary analyses were conducted using MEGA 7 software (Kumar *et al.*, 2016). The phylogenetic tree of EHV-1 ORF68 sequences was constructed using the Neighbor-Joining method. The Kimura 2-parameter method (number of base substitutions per site) was used to estimate the evolutionary distances.

RESULTS

Virus isolation: The presence of characteristic EHV-1 cytopathic effect (CPE) characterized by rounding and detachment of cells was observed in the RK-13 monolayer during the first passage of all 4 inoculated archival EHV-1 samples. During virus isolation, CPE was clear in 51 tissue samples and 19 examined nasal swab samples (Fig. 1).

PCR: The isolation of EHV-1 was confirmed by nested PCR in 47/51 inoculated tissue samples and 17/19 nasal swab samples (Fig. 2). Furthermore, 86/100 examined tissues and 29/42 nasal swab samples were PCR positive for EHV-1 (Table 1). The PCR positive tissue samples originated from 23/25 examined animals. Furthermore, EHV-1 was detected in nasal swabs from 15/16 and 14/16 mares held in two different stables, whilst the 10 stallions from the third stable were negative. All the positive samples of nasal swabs originated from clinically healthy animals, and one yearling with respiratory symptoms was declared negative for EHV-1.



Fig. 1: EHV-1 isolation in RK-13 cell line. (A) RK-13 negative control. (B) Cytopathic effect 48h post-inoculation of sample S19. (C) Cytopathic effect 72h post-inoculation of sample SC25. Arrows point to characteristic cell syncytia (1), cytoplasmic tails (2), and areas with detached cells (3).

ORF30 and ORF68 sequence analysis: Twenty-nine samples were selected for ORF30 gene segment sequencing: 23 tissue samples (one sample per positive animal), 4 archival EHV-1 isolates, and 2 isolates from nasal swabs (one representative from each stable with positive animals). The obtained sequences were aligned and compared with reference EHV-1 G₂₂₅₄ and A₂₂₅₄ genotype sequences from GenBank: strain Ab4 (AY665713.1) and strain V592 (AY464052.1). Four archival EHV-1 strains, both isolates from nasal swabs, and 18 tissue samples belonged to the G₂₂₅₄ genotype, as opposed to 4 tissue samples matching the A₂₂₅₄ genotype. One sequence was unsuitable for analysis, and other SNPs were absent in the analyzed sequences. In total, 82.1% of the representative samples corresponded to the ORF30 G₂₂₅₄ neuropathogenic genotype (Table 2). The analysis of anamnestic data showed no recent outbreaks of neurological disease and/or abortion in the population of animals where the nasal swabs were sampled. The obtained ORF30 sequences were submitted to GenBank (accession numbers: MW316760 - MW316787).

Fifteen sequences were suitable for partial ORF68 gene sequence analysis and originated from 10 tissue samples, 2 isolates from nasal swabs, and 3 archival isolates. The aligned sequences were compared with reference sequences of EHV-1 strains from the proposed geographic groups and unclassified strains. However, only two sequences were convenient for SNP determination in line with previous reports (Nugent et al., 2006; Malik et al., 2012; Stasiak et al., 2017; Matczuk et al., 2018). ORF68 sequences of the two archival EHV-1 isolates contained characteristic SNPs for group 4 (Fig. 3). Other obtained ORF68 sequences in this study could not be classified into any established group and were not further analyzed to get a clear presentation of the results (Table 2). The ORF68 sequences were submitted to GenBank (accession numbers MW316788 and MW316789).

All of the sequenced isolates and strains detected by PCR with relevant data are shown in Table 2.



Fig. 2: Nested PCR results confirming the presence of EHV-1 in examined samples (B, C, D, E). (A) negative sample. (+) positive control (199 bp). (-) negative control - EHV-5 (410 bp).

 Table I: Results of EHV-I detection by virus isolation and PCR in the examined clinical samples

Detection method	٢S	₫LN	۴SC	fM	^g NS	Total
aVI	13	11	15	8	17	64(45.1%)
[▶] PCR	21	21	23	21	29	115(81%)

^a VI (virus isolation); ^b PCR (polymerase chain reaction); ^c S (spleen); ^d LN (submandibular lymph node); ^e SC (spinal column); ^f M (medulla); ^g NS (nasal swab).

570			
420			

	330	340	420	430 5	620	630
				Lessa H Lessa -		
Group 1 Ab4 (AY665713.1)				AACGAA AGAGCO		ATTAGTTCGT
Group 1 GB80_1_2 (DQ172353.1)						
Group 2 US79_1_1 (DQ172394.1)				carearea da las las careas da las las las		
Group 2 US89_1_1 (DQ172408.1)						
Group 3 NL99_1_2 (DQ172372.1)						
Group 3 GB01_1_1 (DQ172334.1) Group 4 DE12_1_1 (KJ513013.1)						
Group 4 FR00 1 1 (DQ172326.1)						
Group 5 US01 2 1 (DQ172376.1)						
Group 5 US03_6_2 (DQ172385.1)						
Group 6 GB85 1 1 (DQ172359.1)						
Group 6 GB01 ⁻² ⁻¹ (DQ172335.1)						
Group 7 78 01 (HQ654054.1)						
Group 8 97 03 (HQ654075.1)						
Group 9 83 01 (HQ654060.1)						
Group 10 04 04 (HQ654069.1)						T
Unclass. PL_1999_II (KY201136.1						A .
Unclass. PL_2001_I (KY201137.1						
Unclass. PL_2013_V(KY201164.1						
Unclass. 93_04 (MH329905.1)						
Unclass. 99_02 (MH329917.1)		 • • • • • • • • • • • • 			T	
Unclass. GB86_3_2 (DQ172361. Unclass. GB87_1_1 (DQ172362.1						
EHV1 A168 (MW316788)						
EHV1_A468 (MW316789)						
EHV1_A400 (MVV310703)				anna a a sua a a		🗖 .
					700	700
	710		20	730 74		760
Group 1 Ab4 (AY665713 1)		- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<u> </u>			
Group 1 Ab4 (AY665713.1) Group 1 GB80 1 2 (DQ172353 1)	GGCCGCT	GCCG CGGCG	G CGGCCGTCC	G AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80_1_2 (DQ172353.1)	GGCCGCT		G CGGCCGTCC	G AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80_1_2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1)	GGCCGCT		G CGGCCGTCC	G AGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79 1 1 (DQ172394.1) Group 2 US89 1 1 (DQ172408.1)	GGCCGCT		G CGGCCGTCC	G AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80_1_2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172394.1) Group 3 NL99_1_2 (DQ172408.1) Group 3 GB01_1_1 (DQ172372.1)	GGCCGCT		G CGGCCGTCC	G AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172408.1) Group 3 NL99_1_2 (DQ172372.1) Group 3 GB01_1_1 (DQ172334.1) Group 4 DE12_1_1 (KJ513013.1)	GGCCGCT	GCCG CGGCGG	G CGGCCGTCC	G AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79 1 1 (DQ172394.1) Group 2 US89 1 1 (DQ172394.1) Group 3 NL99 1 2 (DQ172372.1) Group 3 GB01 1 1 (DQ172374.1) Group 4 DE12 1 (KJ513013.1) Group 4 FR00 1 1 (DQ172326.1)	GGCCGCT	00000000000000000000000000000000000000	G CGGCCGTCC	G AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172408.1) Group 3 NL99_1_2 (DQ172472.1) Group 3 GB01_1 1 (DQ172334.1) Group 4 DE12_1_1 (KJ513013.1) Group 4 FR00_1_1 (DQ172376.1) Group 5 US01_2 1 (DQ172376.1)	GGCCGCT	GCCG CGCGC	G CGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US89_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172394.8) Group 3 NL99_1_2 (DQ172372.1) Group 3 GB01_1_1 (DQ172372.1) Group 4 DE12_1_1 (KJ513013.1) Group 4 FR00_1_1 (DQ172376.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US03_6 2 (DQ1723785.1)		GCCG CGCGC	G CGGCCGTCC	G AGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172372408.1) Group 3 GB01_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172334.1) Group 4 DE12_1_1 (KJ513013.1) Group 4 FR00_1_1 (DQ172326.1) Group 5 US03_6_2 (DQ172385.1) Group 6 GB85_1_1 (DQ172359.1)		GCCG CGGCGC	G CGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_2 (DQ172408.1) Group 3 NL99_1_2 (DQ172472.1) Group 3 OB01_1 (DQ172372.1) Group 4 DE12_1_1 (KJ513013.1) Group 4 FR00_1_1 (DQ172376.1) Group 5 US01_2_1 (DQ172376.1) Group 5 GB85_1_1 (DQ172355.1) Group 6 GB85_1_1 (DQ172355.1)	GGCCGCT		G CGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US89_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172394.1) Group 3 GB01_1_1 (DQ172372.1) Group 4 GE12_1_1 (KJ513013.1) Group 4 FR00_1_1 (DQ172336.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US03_6_2 (DQ172385.1) Group 6 GB85_1_1 (DQ172355.1) Group 6 78_01 (HQ654054.1)	GGCCGCT	GCCG CGCGG	G CGGCCGTC	AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89 1_1 (DQ172372408.1) Group 3 GB01_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172334.1) Group 4 DE12_1-1 (KJ513013.1) Group 4 FR00_1_1 (DQ172326.1) Group 5 US03_6 2 (DQ172385.1) Group 6 GB85_1_1 (DQ172335.1) Group 6 GB85_1_1 (DQ172335.1) Group 6 GB01_2_1 (DQ172335.1) Group 7 78_01 (HQ654054.1) Group 8 97_03 (HQ654075.1)	GGCCGCT	GCCG CGGCGG	G CGGCCGTCC	A GGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_2 (DQ172408.1) Group 3 NL99_1_2 (DQ172472.1) Group 4 GB01_1_1 (DQ172372.1) Group 4 FR00_1_1 (DQ172376.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US03_6_2 (DQ172376.1) Group 5 GB85_1_1 (DQ172355.1) Group 6 GB01_2_1 (DQ172355.1) Group 6 GB01_2_1 (DQ172355.1) Group 7 78 01 (HQ654054.1) Group 8 97_03 (HQ654060.1)	GGCCGCT		G CGGCCGTCC	G AGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US89_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172394.1) Group 3 US89_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172372.1) Group 4 DE12_1_1 (KJ513013.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US03_6_2 (DQ172376.1) Group 6 GB85_1_1 (DQ172376.1) Group 6 GB01_2_1 (DQ172376.1) Group 6 GB01_2_1 (DQ17235.1) Group 7 78_01 (HQ654054.1) Group 9 87_03 (HQ654065.1) Group 9 83_01 (HQ654066.1) Group 9 83_01 (HQ654069.1)	GGCCGCT	GCCG CGGCGG T	G CGGCCGTC	A GGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172372408.1) Group 3 GB01_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172372.1) Group 4 DE12_1-1 (KJ513013.1) Group 4 FR00_1_1 (DQ172326.1) Group 5 US03_6 2 (DQ172385.1) Group 6 GB85_1_1 (DQ172385.1) Group 6 GB85_1_1 (DQ172355.1) Group 6 GB01_2_1 (DQ172355.1) Group 8 G97_03 (HQ654054.1) Group 8 97_03 (HQ654055.1) Group 9 83_01 (HQ654065.1) Group 9 83_01 (HQ654069.1) Unclass. PL_1999_II (KY201136.		GCCG CGGCGG	G CGGCCGTCC	A GGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US89_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172394.1) Group 3 US89_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172372.1) Group 4 DE12_1_1 (KJ513013.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US03_6_2 (DQ172376.1) Group 6 GB85_1_1 (DQ172376.1) Group 6 GB01_2_1 (DQ172376.1) Group 6 GB01_2_1 (DQ17235.1) Group 7 78_01 (HQ654054.1) Group 9 87_03 (HQ654065.1) Group 9 83_01 (HQ654066.1) Group 9 83_01 (HQ654069.1)		GCCG CGGCGG	G CGGCCGTCC	A GGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
$\begin{array}{l} Group 1 \ GB80 \ 1 \ 2 \ [DQ172353.1]\\ Group 2 \ US79_1_1 \ (DQ172394.1)\\ Group 2 \ US89_1_1 \ (DQ172408.1)\\ Group 3 \ NL99_1_2 \ (DQ172372.1)\\ Group 4 \ DE12_1_1 \ (MJ513013.1)\\ Group 4 \ DE12_1_1 \ (MJ513013.1)\\ Group 4 \ DE01_1_1 \ (DQ172326.1)\\ Group 5 \ US01_2_1 \ (DQ172376.1)\\ Group 6 \ GB85_1_1 \ (DQ17235.1)\\ Group 6 \ GB85_1_1 \ (DQ17235.1)\\ Group 7 \ 78 \ 01 \ (HG654054.1)\\ Group 9 \ 93_01 \ (HG654056.1)\\ Group 9 \ 93_01 \ (HG654066.1)\\ Group 10 \ 04_04 \ (HG654066.1)\\ Unclass. \ PL_2001_1 \ (KY201137.1)\\ Unclass. \ 9T_05 \ (MH329914.1)\\ \end{array}$			GCGGCCGTC	AGGCGGGGGA	TGCGCGCCCC	GAGG CGGCGC
$\begin{array}{l} Group 1 \ GB80\ 1\ 2\ (DQ172353.1)\\ Group 2 \ US79_1_1\ (DQ172394.1)\\ Group 2 \ US89_1_1\ (DQ172408.1)\\ Group 3 \ NL99_1_2\ (DQ172372.1)\\ Group 4 \ DE12_1_1\ (KJ513013.1)\\ Group 4 \ DE12_1_1\ (KJ513013.1)\\ Group 5 \ US01_2_1\ (DQ172356.1)\\ Group 5 \ US03_6_2\ (DQ172385.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 7 \ 78_01\ (HQ654054.1)\\ Group 8 \ 97_03\ (HQ654056.1)\\ Group 10 \ 04_04\ (HQ654069.1)\\ Unclass. \ PL_2003_1\ (KY201137.1)\\ Unclass. \ 93_04\ (MH329905.1)\\ \end{array}$			GCGGCCGTC	AGGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US89_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172372.1) Group 3 GB01_1_1 (DQ172372.1) Group 4 DE12_1 (LJ172372.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US01_2_1 (DQ172376.1) Group 6 GB85_1_1 (DQ172385.1) Group 6 GB01_2_1 (DQ172385.1) Group 7 78 01 (HQ654054.1) Group 7 78 01 (HQ654054.1) Group 9 83_01 (HQ654054.1) Group 9 83_01 (HQ654069.1) Unclass. PL_2001_1 (KY201137. Unclass. PL_2001_1 (KY201137. Unclass. PL_2001_1 (KY201136.1) Unclass. 97_05 (MH329914.1) Unclass. 93_04 (MH329905.1) Unclass. 99_02 (MH329917.1)		GCCG CGGCGG	G CGGCCGTCC	A GGGGGGGGA	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_1 (DQ172408.1) Group 3 NL99_1_2 (DQ172372.1) Group 4 GB01_1 (DQ172334.1) Group 4 FR00_1_1 (DQ172336.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US03_6_2 (DQ172376.1) Group 6 GB85_1_1 (DQ172355.1) Group 6 GB01_2_1 (DQ172355.1) Group 8 GB01_2_1 (DQ172355.1) Group 8 GB01_2_1 (DQ172355.1) Group 8 GB01_2_1 (DQ172355.1) Group 9 83_01 (HQ654054.1) Group 9 83_01 (HQ654060.1) Group 9 83_01 (HQ654060.1) Group 9 83_01 (HQ654060.1) Unclass. PL_2001_1 (KY201136.1) Unclass. 97_05 (MH329914.1) Unclass. 93_04 (MH329905.1) Unclass. GB86_3_2 (DQ172361.1)			G CGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC
$\begin{array}{l} Group 1 \ GB80\ 1\ 2\ (DQ172353.1)\\ Group 2 \ US79_1_1\ (DQ172394.1)\\ Group 2 \ US89_1_1\ (DQ172372.1)\\ Group 3 \ NL99_1_2\ (DQ172372.1)\\ Group 4 \ DE12_1_1\ (KJ513013.1)\\ Group 4 \ DE12_1_1\ (KJ513013.1)\\ Group 5 \ US01_2_1\ (DQ172376.1)\\ Group 5 \ US03_6_2\ (DQ172385.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 7 \ 78_01\ (HQ654054.1)\\ Group 9 \ 8 \ 9^{-}03\ (HQ654054.1)\\ Group 9 \ 8 \ 9^{-}03\ (HQ654056.1)\\ Group 9 \ 8 \ 7^{-}03\ (HQ654066.1)\\ Group 9 \ 8 \ 7^{-}05\ (MH329914.1)\\ Unclass. \ PL_2013_V(KY201164.1)\\ Unclass. \ GB86_3_2\ (DQ172365.1)\\ Unclass. \ CB87_1_1\ (DQ172365.1)\\ Unclass. \ CB8$			GCGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC
Group 1 GB80 1 2 (DQ172353.1) Group 2 US79_1_1 (DQ172394.1) Group 2 US89_1_2 (DQ172372.1) Group 3 NL99_1_2 (DQ172372.1) Group 4 GB01_1 (DQ172334.1) Group 4 DE12_1_1 (KJ513013.1) Group 5 US01_2_1 (DQ172376.1) Group 5 US01_2_1 (DQ172376.1) Group 6 GB85_1_1 (DQ172335.1) Group 6 GB85_1_2 (DQ172335.1) Group 6 GB01_2_1 (DQ172335.1) Group 9 87_03 (HG654075.1) Group 9 87_03 (HG654056.1) Unclass. PL_2001_1 (KY201136. Unclass. PL_2001_1 (KY201137. Unclass. 97_05 (MH329914.1) Unclass. 93_04 (MH329905.1) Unclass. GB86_3_2 (DQ172361.1) Unclass. GB86_3_2 (DQ172361.1) Unclass. GB87_1 1 (DQ172362.1)		GCCG CGGCGG	G CGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC
$\begin{array}{l} Group 1 \ GB80\ 1\ 2\ (DQ172353.1)\\ Group 2 \ US79_1_1\ (DQ172394.1)\\ Group 2 \ US89_1_1\ (DQ172372.1)\\ Group 3 \ NL99_1_2\ (DQ172372.1)\\ Group 4 \ DE12_1_1\ (KJ513013.1)\\ Group 4 \ DE12_1_1\ (KJ513013.1)\\ Group 5 \ US01_2_1\ (DQ172376.1)\\ Group 5 \ US03_6_2\ (DQ172385.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 6 \ GB85_1_1\ (DQ172355.1)\\ Group 7 \ 78_01\ (HQ654054.1)\\ Group 9 \ 8 \ 9^{-}03\ (HQ654054.1)\\ Group 9 \ 8 \ 9^{-}03\ (HQ654056.1)\\ Group 9 \ 8 \ 7^{-}03\ (HQ654066.1)\\ Group 9 \ 8 \ 7^{-}05\ (MH329914.1)\\ Unclass. \ PL_2013_V(KY201164.1)\\ Unclass. \ GB86_3_2\ (DQ172365.1)\\ Unclass. \ CB87_1_1\ (DQ172365.1)\\ Unclass. \ CB8$		GCCG CGGCGG	G CGGCCGTCC	G A <u>GGGGGGG</u> A	TGCGCGCCCC	GAGG CGGCGC

Fig. 3: ORF68 gene sequence alignment of Serbian EHV-1 isolates with representative strains of proposed groups and unclassified strains. Identical nucleotides are marked by dots. Nucleotide positions characteristic for ORF68 groups are highlighted.

Table 2: Characteristics of the sequenced EHV-1 strains.

Name	Origin	Isolate	Location	Clinical disease	ORF30 based grouping	ORF68 based grouping
EHVI_AI	archival strain	yes	44.59 N 21.14 E	abortion	G2254	group 4
EHVI_A2	archival strain	yes	44.59 N 21.14 E	abortion	G2254	^b us
EHVI_A3	archival strain	yes	44.59 N 21.14 E	abortion	G2254	°uc
EHVI_A4	archival strain	yes	44.59 N 21.14 E	abortion	G ₂₂₅₄	group 4
EHVI_NS4	nasal swab	yes	44.85 N 17.69 E	none	G ₂₂₅₄	^c uc
EHVI_NSI8	nasal swab	yes	44.85 N 17.69 E	none	G2254	°uc
EHVI_SCI	spinal column	yes	45.2 N 20.4 E	none	G2254	^b us
EHVI_M2	medulla	no	45.2 N 20.4 E	none	G ₂₂₅₄	°uc
EHVI_M3	medulla	yes	45.2 N 20.4 E	none	G ₂₂₅₄	°uc
EHVI_SC4	spinal column	yes	44.23N 22.51E	none	G2254	^b us
EHVI_SC5	spinal column	yes	44.23N 22.51E	none	G2254	^b us
EHVI LN6	^a LN	no	44.23N 22.51E	none	A ₂₂₅₄	^c uc
EHVI_SC7	spinal column	yes	45.22 N 20.23 E	none	G ₂₂₅₄	^c uc
EHVI_LN8	^a LN	no	45.22 N 20.23 E	none	G2254	^b us
EHVI_SCII	spinal column	no	45.02 N 19.81 E	none	us	^b us
EHVI_SI2	spleen	yes	45.02 N 19.81 E	none	G2254	^b us
EHVI_SI3	spleen	no	45.02 N 19.81 E	none	A ₂₂₅₄	°uc
EHVI_MI4	medulla	no	45.02 N 19.81 E	none	G2254	^b us
EHVI_SCI5	spinal column	yes	45.02 N 19.81 E	none	G2254	^b us
EHVI_MI6	medulla	yes	45.02 N 19.81 E	none	A ₂₂₅₄	^b us
EHVI_MI7	medulla	yes	44.49 N 20.27 E	none	G ₂₂₅₄	^b us
EHVI_MI8	medulla	yes	44.49 N 20.27 E	none	G2254	^c uc
EHVI_SI9	spleen	yes	44.53 N 19.23 E	none	A ₂₂₅₄	^c uc
EHVI_SC20	spinal column	yes	44.53 N 19.23 E	none	G ₂₂₅₄	^b us
EHVI_M21	medulla	yes	44.53 N 19.23 E	none	G ₂₂₅₄	^c uc
EHVI_SC22	spinal column	no	44.37 N 20.26 E	none	G2254	^c uc
EHVI_M23	medulla	yes	44.37 N 20.26 E	none	G2254	^b us
EHVI_LN24	^a LN	yes	44.37 N 20.26 E	none	G2254	^c uc
EHVI SC25	spinal column	yes	44.61 N 21.22 E	none	G ₂₂₅₄	^b us

^a LN (submandibular lymph node); ^b us (unsuitable sample); ^c uc (unclassifiable).



Fig. 4: Phylogenetic tree constructed from the ORF68 sequences of 2 Serbian EHV-1 isolates (marked with ♦) and the strain representatives of the 10 proposed geographic groups.

Phylogenetic analysis: A phylogenetic tree was constructed based on the obtained partial ORF68 sequences from the two archival EHV-1 isolates from Serbia and the strain representatives of the 10 proposed geographic groups: group 1 (reference Ab4 strain; GB80_1_2, United Kingdom), group 2 (US79_1_1 and US89_1_1, United States), group 3 (GB01_1_1, United Kingdom; NL99_1_2, Netherlands), group 4 (DE12_1_1, Germany; FR00_1_1, France), group 5 (US01_2_1 and US03_6_2, United States), group 6 (GB85_1_1 and GB01_2_1, United Kingdom), group 7 (78_01, Hungary), group 8 (97_03, Hungary), group 9 (83_01, Hungary), and group 10 (04_04, Hungary). The analysis of the phylogenetic tree confirmed the classification of Serbian EHV-1 isolates based on the marker SNPs (Fig. 4).

DISCUSSION

According to the present study, the majority of analyzed EHV-1 sequences (82.1%) were marked as G₂₂₅₄, indicative of their distribution in Serbia and the Republic of Srpska (Bosnia and Herzegovina). Many studies have examined the presence of EHV-1 strains with neuropathogenic potential in the equine population for a long time, and some even show the rising prevalence of these strains globally (Allen et al., 2008; Gryspeerdt et al., 2011; Castro and Arbiza, 2017; Negussie et al., 2017; Preziuso et al., 2019). The strong correlation of EHM outbreaks and the mentioned EHV-1 strains was frequently demonstrated (Perkins et al., 2009; Gryspeerdt et al., 2011; Barbić et al., 2012; Negussie et al., 2017; Garvey et al., 2019). Moreover, Goodman et al. (2007) presented evidence supporting the assumption of their raised neuropathogenicity. Nevertheless, most of the G₂₂₅₄ strains in our examination were detected in clinically healthy animals. The representative EHV-1 isolates originating from nasal swabs from each of the two stables containing EHV-1 positive mares in this study both harbored the neuropathogenic genetic marker. Anamnestic data show that no cases of neurological disease and/or

abortion have been reported in the examined horse population in the recent period. This supports the hypothesis that the risk factors for EHM development do not depend solely on the virulence of the virus and represent a combination of other host and environmental factors (Lunn et al., 2009; Garvey et al., 2019; Kang et al., 2021). The clinical expression of EHV-1 related disease often remains subclinical and our results demonstrate that this occurrence is not necessarily dependent on the strain involved. There is a possibility that this population of horses is immunologically adapted to infection with equine herpesvirus 1, i.e. that there is a satisfactory level of specific immunity to G₂₂₅₄ strains of the virus that are circulating. Interestingly, the recent detection of strains carrying a new genotype C₂₂₅₄ potentially associated with neurological signs, adds up to the complexity of the viral genotype connection with pathogenicity (Sutton et al., 2020; Pusterla et al., 2021).

The high prevalence of G_{2254} strains in tissue samples from EHV-1 positive horses described in the literature has been observed in our study (Allen et al., 2008; Castro and Arbiza, 2017). These horses were all unvaccinated, clinically healthy, and held in the private sector mostly as working animals. We most commonly detected EHV-1 in the examined tissues by nested PCR, and virus isolation was successful in a smaller number of samples, indicating the existence of low-level or latent EHV-1 infections in the horse population in Serbia. The EHV-1 positive tissues detected in this examination are in line with the findings of other relevant authors who demonstrated its tropism for both lymphoid and neural tissue (Pusterla et al., 2012; Giessler et al., 2020; Samoilowa et al., 2021). Most of the neuropathogenic EHV-1 isolates in our study were detected in the neural tissue that represents a common latency site for this virus, wherefrom it is seldom isolated (Slater et al., 1994; Giessler et al., 2020; Samoilowa et al., 2021). However, Pusterla et al. (2012) specify that latent non-neurotropic strains are more prevalent in the neural tissue of horses, further associating it with the rare occurrence of equine herpes myeloencephalopathy. Other authors underline the importance of the rising prevalence of these latent G2254 strains as an emerging threat (Allen et al., 2008). Nevertheless, the previously reported importance of neural tissue as a site for both latency and reactivation of this virus is also confirmed by our successful isolation of EHV-1 (Slater et al., 1994; Giessler et al., 2020; Samoilowa et al., 2021). The active replication of EHV-1 might be a result of stress during transport to the abattoir and subsequent treatment, whilst the absence of clinical symptoms in these animals raises the question of the potential of stressed asymptomatic carriers as silent shedders of G₂₂₅₄ strains.

Our results confirm that the epizootic abortions during the 1980s at the "Ljubičevo" stud farm were caused by the G_{2254} EHV-1 strains. Similarly, Damiani *et al.* (2014) described abortion cases in a stable in Germany and showed that isolated strains belonged to the neuropathogenic genotype of EHV-1. A considerable connection was recently found between the G_{2254} genotype viruses, multiple abortions, and the occurrence of neurological symptoms (Garvey *et al.*, 2019). Studies

performed in Italy confirmed a high prevalence of G₂₂₅₄ strains in outbreaks involving abortion, further hypothesizing that this variant may be more distributed in this country as opposed to some others (Preziuso et al., 2019). Contrarily, results from some other studies concerning the investigation of the etiology of abortion found little or no correlation outbreaks with neuropathogenic strains of EHV-1 (Perkins et al., 2009; Turan et al., 2012; Stasiak et al., 2017; Matczuk et al., 2018; Stasiak et al., 2020). Sutton et al. (2019) suggest "neuropathogenic/non-neuropathogenic" that the classification is not consistent and further demonstrate a strong connection of EHV-1 A₂₂₅₄ genotype and abortion cases. Fritsche and Borchers (2011) examined the prevalence of G₂₂₅₄ strains among isolates from equine abortions in Germany, as well as among archived isolates collected in the period from 1987 to 2009. In contrast to our results, only 10.6% of EHV-1 isolates possessed a neuropathogenic genetic marker.

The analysis of the ORF68 gene fragment yielded only two sequences suitable for SNP analysis according to prior studies (Nugent et al. 2006; Malik et al., 2012; Stasiak et al., 2017; Matczuk et al., 2018). The ORF68 sequences of two isolates from abortion cases were characterized by SNPs typical for the fourth geographical group of EHV-1 (presence of A instead of G at position 629), consisting mostly of European strains. Damiani et al. (2014) also reported comparable results during their investigation of abortion outbreaks in Germany. Moreover, a study conducted by Negussie et al. (2017) showed that EHV-1 isolates from Ethiopia were also categorized to group 4. Our results indicate that ORF68 does not represent a suitable molecular marker for the analysis of EHV-1 strains from this study. Also, the primers reported by Nugent et al. (2006) are probably not specific enough to properly bind to the genetic segment of the ORF68 gene of domestic EHV-1 strains due to its pronounced polymorphism. Malik et al. (2012) classified Hungarian EHV-1 isolates from abortion cases in the period from 1977 to 2008 into several geographical groups, with only 23 of the 35 examined isolates belonging to the groups previously described by Nugent et al. (2006). Single nucleotide polymorphisms in the sequences of the remaining 12 isolates conditioned the creation of 4 additional geographical groups. As observed in our examination, these data show that EHV-1 strains from this part of Europe demonstrate specific polymorphism, which would induce the creation of numerous groups, thus questioning the purpose of this division. According to Malik et al. (2012), the EHV-1 strains from group 7 were introduced from Serbia during the transport of horses to Germany via Hungary, however, no viruses from this group were detected in our study. Similar results for Eastern European strains were reported by Stasiak et al. (2017, 2020), who characterized EHV-1 isolates originating from cases of abortion dating from 1999 to 2017. Most of the examined sequences were not classified in any of the groups according to Nugent et al. (2006), whereas the remaining sequences were assorted in groups 3 and 4. The authors further concluded that ORF68 is not a reliable molecular marker for conducting epizootiological studies of infections caused by EHV-1. Moreover, most EHV-1 strains (76.9%) isolated from

equine abortions in Poland from 1993 to 2017 were also unclassifiable, and the rest belonged to groups 2 and 4 (Matczuk et al., 2018). Similar to our study, Preziuso et al. (2019) reported failed tests using previously reported ORF68 primers for the analysis of 20 archival EHV-1 strains from abortion cases in Italy. The authors designed new primers, and a total of 7 sequences were appropriate for examination showing that none could be classified using the proposed grouping system. Furthermore, EHV-1 strains from a recent Korean study also remained unclassified regarding the ORF68 gene polymorphism (Kang et al., 2021). A recent examination demonstrated that EHV-1 strains from Ireland were not geographically limited underlining the ORF68 is not an applicable genetic marker and proposed multi-locus analysis as an improved approach to EHV-1 strain typing (Garvey et al., 2019; Kang et al., 2021).

Conclusions: The presented results contribute to the knowledge of the distribution, diversity, and clinical implications of EHV-1 strains circulating in the equine population in the region of Serbia and Bosnia and Herzegovina. The designation of an EHV-1 strain as neuropathogenic is not sufficient in terms of determining its significance in a clinical sense, and other factors such as host immunity and infection form should also be taken into account. Asymptomatic horses shed the virus and are a potential source of EHV-1 for other horses, which requires proper control strategies. EHV-1 exhibits tropism towards lymphoid and neural tissues of horses, and the significance of neural tissue in the cycles of virus reactivation is also demonstrated. The ORF68-based strain analysis is not applicable for the examined Balkan strains owing to their polymorphism, and more specific primers should be designed for such studies.

Acknowledgements: The study was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Contract number 451-03-9/2021-14/200143).

Authors contribution: JN, NM, and AR planed and designed the study; AR and OS collected the samples; JN and AR carried out virus isolation and molecular genetic studies; LJV assisted in virus isolation. AR and OS interpreted results and drafted the manuscript. NM, JN and LJV assisted in drafting the manuscript and critically revised the manuscript. All authors have read the manuscript and approved submission of the manuscript.

REFERENCES

- Allen GP, Bolin DC, Bryant U, et al., 2008. Prevalence of latent, neuropathogenic equine herpesvirus-I in the Thoroughbred broodmare population of central Kentucky. Equine Vet J 40:105-10.
- Barbić L, Lojkić I, Stevanović V, et al., 2012. Two outbreaks of neuropathogenic equine herpesvirus type I with breed-dependent clinical signs. Vet Rec 170:227.
- Castro ER and Arbiza J, 2017. Detection and genotyping of equid herpesvirus I in Uruguay. Rev Sci Tech 36:799-806.
- Damiani AM, de Vries M, Reimers G, et al., 2014. A severe equine herpesvirus type I (EHV-1) abortion outbreak caused by a neuropathogenic strain at a breeding farm in northern Germany. Vet Microbiol 172:555-62.

- Fritsche A-K and Borchers K, 2011. Detection of neuropathogenic strains of Equid Herpesvirus 1 (EHV-1) associated with abortions in Germany. Vet Microbiol 147:176-80.
- Garvey M, Lyons R, Hector RD, et al., 2019. Molecular Characterisation of Equine Herpesvirus I Isolates from Cases of Abortion, Respiratory and Neurological Disease in Ireland between 1990 and 2017. Pathog (Basel, Switzerland) 8.
- Giessler KS, Samoilowa S, Soboll Hussey G, et al., 2020. Viral load and cell tropism during early latent equid herpesvirus I infection differ over time in lymphoid and neural tissue samples from experimentally infected horses. Front Vet Sci 7:621.
- Goodman LB, Loregian A, Perkins GA, et al., 2007. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog 3:e160.
- Gryspeerdt A, Vandekerckhove A, JV, et al., 2011. Description of an unusually large outbreak of nervous system disorders caused by equine herpesvirus I (EHV-1) in 2009 in Belgium. Vlaams Diergeneeskd Tijdschr 80:147-53.
- Kang H-W, Lee E-Y, Lee K-K, et al., 2021. Evaluation of the Variability of the ORF34, ORF68, and MLST Genes in EHV-1 from South Korea. Pathogens 10.
- Kumar S, Stecher G and Tamura K, 2016. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol 33:1870-4.
- Lunn DP, Davis-Poynter N, Flaminio MJBF, et al., 2009. Equine Herpesvirus-I Consensus Statement. J Vet Intern Med 23:450-61.
- Malik P, Bálint A, Dán A, et al., 2012. Molecular characterisation of the ORF68 region of equine herpesvirus-I strains isolated from aborted fetuses in Hungary between 1977 and 2008. Acta Vet Hung 60:175-87.
- Matczuk AK, Skarbek M, Jackulak NA, et al., 2018. Molecular characterisation of equid alphaherpesvirus I strains isolated from aborted fetuses in Poland. Virol J 15:186.
- Milić N, Radalj A and Nišavić J, 2018. Standard and molecular methods in the diagnostics of infections caused by equine herpesviruses I and 4. Vet Glas 72:68-79.
- Negussie H, Gizaw D, Tessema TS, *et al.*, 2017. Equine Herpesvirus-I Myeloencephalopathy, an Emerging Threat of Working Equids in Ethiopia. Transbound Emerg Dis 64:389-97.
- Nugent J, Birch-Machin I, Smith KC, et al., 2006. Analysis of equid herpesvirus I strain variation reveals a point mutation of the DNA

polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J Virol 80:4047-60.

- Perkins GA, Goodman LB, Tsujimura K, et al., 2009. Investigation of the prevalence of neurologic equine herpes virus type I (EHV-1) in a 23-year retrospective analysis (1984–2007). Vet Microbiol 139:375-8.
- Preziuso S, Sgorbini M, Marmorini P, *et al.*, 2019. Equid alphaherpesvirus I from Italian Horses: Evaluation of the Variability of the ORF30, ORF33, ORF34 and ORF68 Genes. Viruses I I.
- Pusterla N, Barnum S, Miller J, et al., 2021. Investigation of an EHV-1 outbreak in the United States caused by a new H752 genotype. Pathogens 10.
- Pusterla N, Mapes S and Wilson WD, 2012. Prevalence of latent alphaherpesviruses in Thoroughbred racing horses. Vet J 193:579-82.
- Samoilowa S, Giessler KS, Torres CEM, et al., 2021. Equid herpesvirus-I distribution in equine lymphoid and neural tissues 70 days post infection. Pathogens 10.
- Slater J, 2014. Chapter 14 Equine herpesviruses. In: equine infectious diseases (Sellon DC and Long MT, eds). 2nd Ed, WB Saunders: St. Louis, USA, pp:151-68.e8.
- Slater JD, Borchers K, Thackray AM, et al., 1994. The trigeminal ganglion is a location for equine herpesvirus I latency and reactivation in the horse. J Gen Virol 75:2007-16.
- Stasiak K, Dunowska M and Rola J, 2020. Outbreak of equid herpesvirus I abortions at the Arabian stud in Poland. BMC Vet Res 16:374.
- Stasiak K, Dunowska M, Hills SF, et al., 2017. Genetic characterization of equid herpesvirus type I from cases of abortion in Poland. Arch Virol 162:2329-35.
- Sutton G, Garvey M, Cullinane A, et al., 2019. Molecular surveillance of EHV-1 strains circulating in france during and after the major 2009 outbreak in normandy involving respiratory infection, neurological disorder and abortion. Viruses 11.
- Sutton G, Thieulent C, Fortier C, et al., 2020. Identification of a new equid herpesvirus I DNA polymerase (ORF30) genotype with the isolation of a C(2254)/H(752) strain in French horses showing no major impact on the strain behaviour. Viruses 12:1160.
- Turan N, Yildirim F, Altan E, et al., 2012. Molecular and pathological investigations of EHV-1 and EHV-4 infections in horses in Turkey. Res Vet Sci 93:1504-7.
- Wang L, Raidal SL, Pizzirani A, et al., 2007. Detection of respiratory herpesviruses in foals and adult horses determined by nested multiplex PCR. Vet Microbiol 121:18-28.